1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Ashraf Badros: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma MK-3475, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Ashraf Badros | 48 | 2014-12-30 | 2019-11-05 |
Multiple Myeloma (1) · Recurrence (1)
Calcium Dobesilate (1) · Dexamethasone (1) · pembrolizumab (1) · pomalidomide (1)
United States (1)
Ashraf Z Badros, M.B.,Ch.B (1)